<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528760</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-005</org_study_id>
    <nct_id>NCT02528760</nct_id>
  </id_info>
  <brief_title>To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis</brief_title>
  <official_title>To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis- A Randomized Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. All patients with chronic liver disease admitted in ICU (Intensive Care Unit) to be&#xD;
           screened.&#xD;
&#xD;
        2. Patients fulfilling criteria for feed intolerance to be included in the study.&#xD;
&#xD;
        3. Patients to undergo routine biochemical and hematological testing including CBC, KFT,&#xD;
           LFT, PT/INR, electrolytes baseline and daily along with ABG (Arterial Blood gas)&#xD;
           analysis.&#xD;
&#xD;
        4. Patients with ascites to be tested for presence or absence of SBP (Spontaneous Bacterial&#xD;
           Peritonitis).&#xD;
&#xD;
        5. Cultures to be sent as based on clinical parameter of the patient.&#xD;
&#xD;
        6. All correctable causes for intra abdominal hypertension to be corrected including&#xD;
           electrolyte imbalance, grade III ascites, intra abdominal infection.&#xD;
&#xD;
        7. Symptoms- Absent bowel sounds (BS)= no BS detected by auscultation.&#xD;
           Vomiting/regurgitation= any visible regurgitation of gastric contents; Diarrhoea= liquid&#xD;
           stool &gt; or =3 times/day; Bowel distension= suspected clinically and radiologically&#xD;
           confirmed; Large gastric residual volume (GRV) of &gt;or =500 ml/24 h on a single day or &gt;&#xD;
           200ml at any time of the day.&#xD;
&#xD;
        8. Per abdomen findings to be checked daily including presence of bowel sounds, tenderness,&#xD;
           development of abdominal distension, abdominal girth monitoring and abdominal pressure&#xD;
           monitoring.&#xD;
&#xD;
        9. Patients who develop feed intolerance will be included.&#xD;
&#xD;
       10. Feed intolerance to be defined as per study definition (3 out of 5 symptoms).&#xD;
&#xD;
       11. Measurement of GRV (Gastric residual volume) to be done at 4 hourly interval.&#xD;
&#xD;
       12. Methods for measuring GRV by either gravity drainage by connecting a gastric tube to a&#xD;
           drainage bag for 10min or by manual aspiration of content using a 50ml syringe.&#xD;
&#xD;
       13. Once feed intolerance develop than every 6 hourly intra abdominal pressure monitoring&#xD;
           and abdominal girth monitoring to be done (24)&#xD;
&#xD;
       14. Intra bladder pressure to be measured using Foleys manometer technique (25).&#xD;
&#xD;
       15. Pressure measured in cm of water to be converted into mm of Hg.&#xD;
&#xD;
       16. X ray abdomen supine to look for bowel distension, defined as more than 3 cm for small&#xD;
           bowel and more than 5 cm in large bowel.&#xD;
&#xD;
       17. Development of intra abdominal hypertension based on intra abdominal pressure.&#xD;
&#xD;
       18. Patient to be stratified according to the grade of intra-abdominal hypertension.&#xD;
&#xD;
       19. After correction of all correctable causes, if feed intolerance persists, then patient&#xD;
           to be randomized by block randomization method into 3 arms, metaclopromide group,&#xD;
           erythromycin group or placebo group.&#xD;
&#xD;
       20. Daily assessment of bowel sounds, abdominal pressure, abdominal girth every 6 hourly and&#xD;
           gastric residual volume to be noted every 4 hourly.&#xD;
&#xD;
       21. Response of therapy to be assessed at 24 hours in each arm.&#xD;
&#xD;
       22. Response to be assessed by resolution of feed intolerance or initiation of entral&#xD;
           nutrition.&#xD;
&#xD;
       23. Metoclopromide to be given 10mg iv 8 hourly.&#xD;
&#xD;
       24. Erythromycin to be given 70mg iv 12 hourly (26).&#xD;
&#xD;
       25. Placebo arm to receive normal saline in 10ml syring twice daily.&#xD;
&#xD;
       26. After 24 hours of treatment if symptoms do not resolve than rescue treatment will be&#xD;
           given to each arm which may include continuation of prokinetics, add on prokinetic,&#xD;
           flatus tube insertion for bowel decompression, upgradation of antibiotics or search for&#xD;
           any other cause, as per the patient response.&#xD;
&#xD;
       27. Therapy to continue for a total duration of 72 hours.&#xD;
&#xD;
       28. If there is no response at 72 hours, than study stops.&#xD;
&#xD;
       29. If patient responds to given treatment, study to continue for a total duration of 7&#xD;
           days.&#xD;
&#xD;
       30. Assessment to continue in each arm for a maximum period of 7 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2015</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of feed intolerance at 24 hours with improvement in 3 or more points and initiation of entral feeding.</measure>
    <time_frame>24 hours</time_frame>
    <description>Feed intolerance to be defined as 3/5 symptoms which include gastric residual volume &gt; 500 ml /day,absence of bowel sounds,vomitting/regurgitation,diarrhoea and bowel distension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Initiation of entral nutrition more than 50%. of recommended nutrition (Kcal/kg body weight/day).</measure>
    <time_frame>72 hours</time_frame>
    <description>Feed intolerance is also defined when entral nutrition provided &lt; 20Kcal/kg body weight/day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with resolution of atleast 2 out of 5 symptoms in all the 3 groups.</measure>
    <time_frame>72 hours</time_frame>
    <description>Feed intolerance to be defined as 3/5 symptoms which include gastric residual volume &gt; 500 ml /day,absence of bowel sounds,vomitting/regurgitation,diarrhoea and bowel distension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with resolution of sepsis, shock, organ failure in all the 3 groups.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients without Ventilatory support in all the 3 groups.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients without inotropic supports in all the 3 groups.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Metaclopromide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythromycin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metaclopramide</intervention_name>
    <description>23. Metoclopromide to be given 10mg iv 8 hourly</description>
    <arm_group_label>Metaclopromide group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <description>Erythromycin to be given 70mg iv 12 hourly.</description>
    <arm_group_label>Erythromycin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Patients who develop new onset feed intolerance to enteral nutrition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any patient with current or past surgical abdomen including mechanical obstruction,&#xD;
             mesenteric ischemia, perforation or requiring abdominal surgery.&#xD;
&#xD;
          2. Patients receiving enteral nutrition through gastrostomy or jejunostomy.&#xD;
&#xD;
          3. Patients in whom, prokinetics are contraindicated or are allergic to the same.&#xD;
&#xD;
          4. Patients who received prokinetic more than one day prior to the start of enteral&#xD;
             feeding.&#xD;
&#xD;
          5. Patients with uncontrolled sepsis with DIC.&#xD;
&#xD;
          6. Requirement of two or more vasopressors.&#xD;
&#xD;
          7. Organ failure requiring high inotropic support.&#xD;
&#xD;
          8. Advanced cardiopulmonary disease, with prior history of arrhythmias, structural heart&#xD;
             disease.&#xD;
&#xD;
          9. History of traumatic brain injury, raised intracranial pressure, history of myasthenia&#xD;
             gravis.&#xD;
&#xD;
         10. Endocronolgic illnesses: Hypothyroidism, hypoparathyroidism&#xD;
&#xD;
         11. Connective tissue diseases (systemic sclerosis, dermatomyositis or polymyositis,&#xD;
             systemic lupus erythematosis, amyloidosis).&#xD;
&#xD;
         12. Known case of diabetes with diabetic gastroparesis&#xD;
&#xD;
         13. Pregnancy&#xD;
&#xD;
         14. Patients or concerned family member who fail to give consent for study enrollment&#xD;
&#xD;
         15. Age less than 18 years and more than 70 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>November 18, 2017</last_update_submitted>
  <last_update_submitted_qc>November 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

